⚠ The mpox vaccine is available for those who are eligible. At this time the vaccine is not available for the general public looking to get vaccinated for travel purposes. Please review the eligibility criteria for the vaccine before booking an appointment, visiting our clinic or calling Ottawa Public Health.
Last revised: November 25, 2024
Current Situation
Mpox was first reported in Canada in 2022 as part of the global outbreak of sub-clade IIb. Sub-clade IIb continues to cause mpox infections in Ontario in 2024, including Ottawa, though fewer than during the 2022 outbreak.
On August 14, 2024, the World Health Organization again declared mpox to be a Public Health Emergency of International Concern due to ongoing outbreaks and the spread of the more severe strain of the virus (sub-clade Ib) in countries in West and Central Africa. Sub-clade Ib has been reported in Canada, with no sustained transmission reported to date. The Public Health Agency of Canada (PHAC) reports the risk of mpox to the general population remains low.
The majority of people who have tested positive for mpox in Ontario and Canada identify as males and report intimate sexual contact with same sex partners, however other groups can be affected. Most cases do not report having traveled, suggesting ongoing localized transmission in Canada and Ontario. Severity of cases in Canada remains low, with rare hospitalizations and no deaths reported to date.
In Ontario, the Ministry of Health has guidance on who can receive the mpox vaccine, to ensure that it continues to be available to groups at the highest risk of transmission. Residents are encouraged to confirm their eligibility for the vaccine before visiting a clinic or contacting Ottawa Public Health. Outside of existing eligibility criteria, persons traveling are not eligible for mpox vaccine. The Government of Canada has mpox advice available for travelers.
Ottawa Public Health continues to monitor the situation closely and encourages people at greater risk to get vaccinated. Public Health Ontario publishes a biweekly report that provides an epidemiologic summary of confirmed mpox cases in Ontario. The Public Health Agency of Canada has further information on mpox in Canada and globally.
What is Mpox (monkeypox)?
Mpox is a rare viral disease caused by a virus usually found to be endemic in Central and Western Africa. Since May 2022, there have been cases of mpox in several countries where the disease is not normally found, including Canada. Ottawa Public Health announced the first confirmed case of mpox in Ottawa on June 17, 2022. The virus enters the body through broken skin, the respiratory tract or the mucous membranes, like the eyes, nose, or mouth. Mpox symptoms typically last from 2 to 4 weeks. In some cases, people can develop health complications from mpox which can lead to severe outcomes. Safe and effective vaccination along with prevention measures such as practicing safe sex, limiting the number of sexual partners, isolation when having symptoms, and avoiding sharing objects with a person with mpox will limit the spread of the virus.
Anyone can get infected and spread mpox if they come into close contact with someone who has the virus, regardless of sex, race, gender or sexual orientation. The mpox virus can affect anyone who is in close contact with an infected person such as direct contact with their body fluids, respiratory droplets, sores or by coming into contact with items they may have been in contact with. Currently, person to person transmission is occurring in Canada. In line with international trends, the majority of cases in Canada to date are men who reported intimate sexual contact with other men. However, it's important to stress that the risk of exposure to the mpox virus is not exclusive to any group or setting. According to the Public Health Agency of Canada (PHAC) the risk of infection is low for the general population.
What is Ottawa Public Health’s role?
Ottawa Public Health will follow up with and provide guidance and self-isolation instructions to those who are confirmed to have mpox and any possible contacts. Ottawa Public Health continues to work closely with the Ministry of Health and Public Health Ontario, local infectious disease experts and health care providers to limit the spread of mpox in the community.
Symptoms, prevention and testing
Commons signs and symptoms |
The incubation period (time between exposure/ infection and when symptoms begin) is typically six to 13 days, and can be up to 21 days. Mpox infection can appear similar to other infectious diseases, such as chickenpox, or several sexually transmitted infections (such as herpes or gonorrhea). This is why it's important to consult a health care provider and be tested. If you think that you may have the signs and symptoms of mpox, and or are a close contact of someone who has confirmed mpox, please contact your health care provider for an assessment as soon as possible. Limit your contact with others and self-isolate. Most transmission of mpox in Canada has occurred between close contacts like intimate partners or household members. |
Think you may have been exposed to mpox? |
If you think you may have come in contact with someone who has symptoms of mpox, you should monitor yourself for symptoms for 21 days and contact Ottawa Public Health at 613-580-6744 for further assessment to see if post exposure prophylaxis, vaccination or testing is recommended. If no symptoms appear after 21 days, you can continue with normal activities. If symptoms develop, you should self-isolate immediately and get tested for mpox. How to get tested for mpoxThere are two ways to get tested for mpox in Ottawa.
|
What to do if you have been tested for mpox |
If you have been tested for mpox, it is important to self-isolate at home until you receive negative test results. Ottawa Public Health will follow up with you if your test result is positive and advise on next steps. If you test positive for mpox you should self-isolate at home until lesion scabs have fallen off and new intact skin has formed below. This recovery period typically takes two to four weeks. If you have been tested for mpox or are experiencing symptoms you should:
|
How to prevent the spread of mpox |
To lower your overall risk of getting infected with and spreading the mpox virus, we recommend to:
Our observations are that close sexual contact remains the primary way that mpox is being transmitted in our community. If airborne transmission played a more significant role in overall transmission of mpox, we would anticipate a greater incidence of sporadic infections in the community across different age groups and demographics. In line with international trends, the majority of cases in Canada to date are men who reported intimate sexual contact with other men. However, it's important to stress that the risk of exposure to the mpox virus is not exclusive to any group or setting. According to the Public Health Agency of Canada (PHAC) the risk of infection is low for the general population. |
Vaccination
Imvamune® is a vaccine given in a two dose series that helps protect against mpox infection. Imvamune® is a live, non-replicating vaccine. The vaccine contains a very weakened form of a virus similar to the one that causes mpox and cannot make you sick. When a person is given the vaccine, the immune system will produce its own protection in the form of antibodies against the virus. A single dose is expected to provide reasonable protection by two to four weeks following vaccination. A second dose produces a slightly higher response and may provide longer-lasting protection. Imvamune® can be used to protect individuals before an exposure to the mpox virus (this is called Pre-Exposure Prophylaxis or PrEP) or to protect individuals after being exposed to the mpox virus (this is called Post-Exposure Prophylaxis or PEP).
Getting your mpox vaccine |
||||||||||
Who can receive the Imvamune® vaccine for protection before an exposure to the mpox virus?Anyone who received one dose of the Imvamune® mpox vaccine can now receive a second dose at least 28 days after receiving their first dose. This includes individuals who received the vaccine for protection before or after an exposure to the mpox virus. Based on the Ontario Ministry of Health guidelines, the following groups are eligible for a 2-dose series of the Imvamune® vaccine for protection. a) Two-spirited, non-binary, transgender, cisgender, intersex, or gender-queer individuals who self-identify or have sexual partners who self-identify as belonging to the gay, bisexual, pansexual and other men who have sex with men (gbMSM)
b) Individuals who self-identify as engaging in sex work or are planning to, regardless of self-identified sex or gender. c) Household and/or sexual contacts of those identified for pre-exposure vaccination eligibility in parts (a) and/or (b) above AND who are moderately to severely immunocompromised or pregnant may be considered for pre-exposure vaccination. These individuals may be at higher risk for severe illness from a mpox infection and should contact their healthcare provider or Ottawa Public Health at 613-580-6744 for more information. Imvamune® vaccine eligibility after being exposed to the mpox virusIf you have been identified as a high risk contact or an intermediate risk contact of a confirmed or probable case of mpox, you will be contacted by Ottawa Public Health directly and may be offered an appointment to receive the mpox vaccine for Post-Exposure Prophylaxis (PEP). Frequently asked questions
|
||||||||||
View clinic location |
||||||||||
Clinic location: OPH Clinic - 179 Clarence Street, Ottawa Second doses:
|
||||||||||
Who should not receive the Imvamune® mpox vaccine? |
||||||||||
Anyone who does not meet the current eligibility criteria outlined by the Ontario Ministry of Health is not eligible to receive the mpox vaccine. Individuals who have been a confirmed case of mpox since 2022, are NOT recommended to receive the mpox vaccine at this time; this is based on the limited utility of the vaccine given that these persons are expected to have natural immunity due to recent infection. Individuals who have received two doses of Imvamune® in 2022 or later or not eligible for additional doses. People with signs and symptoms of mpox infection should NOT receive the Imvamune® mpox vaccine as it is not intended for the treatment of mpox. Do not attend an Imvamune® clinic if you have symptoms. People who have a confirmed allergy to any of the vaccine ingredients listed below or its container are not recommended to receive the mpox vaccine. Ingredients of the Imvamune® vaccine are:
Imvamune® may also contain trace amounts of gentamicin, ciprofloxacin and egg products (egg cell DNA and protein). As per the Ministry of Health, individuals with a known allergy to these ingredients are still able to safely receive Imvamune®. People with a history of anaphylaxis after a previous dose of an Imvamune® vaccine are not recommended to receive the vaccine. |
||||||||||
What should I expect after I receive the vaccine? |
||||||||||
Side effects may develop in the few days after receiving the vaccine. Although most of these side effects are not serious to your health, they may make you feel unwell for a few days. The side effects should go away on their own. Common side effects of Imvamune® include pain, swelling, redness and itchiness at the injection site where the needle was given. Applying a cool, damp cloth where the vaccine was given may help with pain and swelling. Other common side effects can include fatigue, headache, body aches, nausea, loss of appetite, joint pain, chills and fever. If needed, pain or fever medication (such as acetaminophen or ibuprofen) may help. People who have atopic dermatitis (eczema) may experience more side effects than others and may also experience a flare-up or worsening of their condition. If you develop any serious signs or symptoms that could be an allergic reaction within four hours of being vaccinated, call 9-1-1 right away. Symptoms of an allergic reaction include:
You should also seek medical attention right away if you develop any symptoms that could be related to your heart such as chest pain or discomfort, shortness of breath, and a fast or irregular heartbeat. If you have concerns about the symptoms you develop after receiving the vaccine, contact your healthcare provider. Any adverse events following vaccination should be reported to your local public health unit. |
||||||||||
Is the vaccine safe and effective? |
||||||||||
Yes, Imvamune® is safe to receive. If you received another vaccination in the past 4 weeks, please let your health care provider know before getting Imvamune®. If you are less than 18 years of age, pregnant, breastfeeding, or are immunocompromised you should speak to your health care provider. Your health care provider will review the risks and benefits of receiving the mpox vaccine. We know that vaccination is not a 100% guarantee of not being infected with the virus that causes mpox. A single dose is expected to provide reasonable protection by two to four weeks following vaccination. A second dose produces a slightly higher response and may provide longer-lasting protection. It takes around 14 days for your immune system to build up protective immunity to mpox. Waiting a full month after vaccination before resuming higher risk sexual contact, using condoms, staying home when having symptoms and having fewer sexual partners helps lower the risk of getting mpox. |
Mpox cases in Ottawa
If you want to know more about the numbers of confirmed, suspect or probable cases, you can visit the Public Health Ontario page (updated Tuesdays and Fridays).
Background information
- Mpox: Outbreak update (Government of Canada)
- Mpox: Questions and answers (World Health Organization)
- About mpox (USA Centers for Disease Control and Prevention)
- Mpox virus overview: including transmission and clinical signs / symptoms (Ontario Ministry of Health)
- Mpox detailed fact sheet : Provides an overview of the virus, transmission, epidemiology, clinical considerations including treatment, case and contact management, and prevention (World Health Organization)
- Mpox: What we know (Gay Men's Sexual Health Alliance)
Contact Us